The Respiratory Syncytial Virus (RSV) Therapeutics Market exhibited substantial growth, with a valuation of USD 5.75 billion in 2023, as reported by recent data. Projections suggest a remarkable upward trajectory, with expectations indicating a surge to USD 15.28 billion by 2031. This anticipated expansion reflects a robust compound annual growth rate (CAGR) of 13% over the forecast period spanning from 2024 to 2031. Such promising figures underscore the growing importance and demand for effective therapeutics targeting respiratory syncytial virus infections. As advancements in medical research and pharmaceutical development continue, this market is poised for significant evolution, aiming to address the challenges posed by RSV and enhance patient outcomes.